Historically KuDOS Pharma (acquired by AstraZeneca) reported a series of small molecule ATM inhibitors.205 These ATM inhibitors failed to cause cytotoxic effect as single agent, but sensitized cancer cells to DSB inducers such as radiation and topoisomerase inhibitors. This evidence concerns the gene ATM and cancer.